At least half of patients with crizotinib-resistant ALK translocation-positive non-small-cell lung cancer respond to treatment with the new-generation ALK inhibitor ensartinib, including those with brain metastases, phase II study data show.
The reduced prostate cancer risk seen in men with diabetes may be partly explained by detection bias due to a lower biopsy rate following an elevated prostate-specific antigen test result, population-based study data show.
Adding docetaxel, abiraterone acetate, enzalutamide, or apalutamide to androgen deprivation therapy significantly improves survival for men with metastatic hormone-sensitive prostate cancer, with little difference between each drug, a network meta-analysis shows.
The early potential of lorlatinib for the treatment of patients with advanced ROS1-positive non-small-cell lung cancer who are either tyrosine kinase inhibitor-naïve or have previously received crizotinib has been re-emphasized in the expanded analysis of a phase I–II trial.
In immune checkpoint inhibitor-treated patients with non-small-cell lung cancer, co-mutation in TP53 and ATM isassociated with a higher tumor mutational burden and better overall survival versus one or no mutations, according to a multi-cohort study.
A one-off post-hoc analysis of the GETUG-AFU 16 study has confirmed the long-term benefit of adding short-term androgen suppression to radiotherapy for salvage treatment in patients with increasing prostate-specific antigen concentration after radical prostatectomy.
Osimertinib and gefitinib plus pemetrexed-based chemotherapy offer the best survival outcomes for patients with advanced EGFR-mutated non-small-cell lung cancer compared with other first-line treatments, shows a network meta-analysis of randomized trials.
An analysis of the SEER–Medicare database has confirmed the link between use of 5α-reductase inhibitors, primarily for benign prostatic enlargement, and increased risk for prostate cancer-specific and all-cause mortality.
Studies presented at the ESMO 2019 Congress propose that patients with metastatic renal cell carcinoma may benefit from a combination of nivolumab and the VEGFR tyrosine kinase inhibitor tivozanib, or by continuing with single-agent nivolumab past initial disease progression.
Using a life–years gained approach to select patients for lung cancer screening could maximize its benefits for current and ex-smokers who have both a high risk for lung cancer and a long life expectancy, US research suggests.
Receipt of the Bacillus Calmette-Guérin vaccine may reduce the risk for developing lung cancer, suggests a secondary analysis of a clinical trial conducted in American–Indian and Alaska Native populations.
Time spent off treatment could be used as a novel clinical trial endpoint for patients undergoing renal cell carcinoma immunotherapy, suggest study findings reported at the ESMO Congress 2019 in Barcelona, Spain.
An electronic nose can predict if patients with advanced non-small-cell lung cancer will respond to immune checkpoint inhibitor therapy by analyzing the composition of volatile organic compounds in patients’ exhaled breath, say researchers.
Results from the ADAPTeR study suggest that giving nivolumab before and after cytoreductive nephrectomy or metastatic biopsy may be a feasible strategy for patients with treatment-naïve metastatic clear cell renal cell carcinoma.
Analysis of data from the PACIFIC trial shows that levels of key patient-reported outcomes such as cough, fatigue, and quality of life, do not differ significantly between patients with advanced non-small-cell lung cancer treated with durvalumab after chemoradiotherapy and those who received placebo.